



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyyssw@sina.com

产品名称: **MSC2504877**

CAS 号: **1460286-21-8**

产品货号: **S89867**

生物活性:

Description	MSC2504877 (M2912) is a potent and orally active tankyrase inhibitor with IC50s of 0.0007, 0.0008, 0.54 μM for TNKS, TNKS2, PARP1, respectively. MSC2504877 increases the expression of AXIN2 and TNKS protein levels and decreases β-catenin levels. MSC2504877 shows anti-tumor activity[1].																				
IC50 & Target	PARP1 0.54 μM (IC50)	TNKS 0.0007 μM (IC50)	TNKS2 0.0008 μM (IC50)																		
In Vitro	MSC2504877 (1, 3, 10 μM; 24 小时) 增加 APC 突变体 COLO320DM 结直肠肿瘤细胞中 AXIN2 和 TNKS 蛋白水平的表达并降低 β-catenin 蛋白水平[1]。 MSC2504877 (0-100 μM; 5 天) 抑制 APC-/- 细胞和 COLO320DM 细胞的存活[1]。 MSC2504877 (1 μM; 24 小时) 与 albociclib (0.03 μM) 联合使用可诱导细胞周期停滞在 G1 期[1]。 Western Blot Analysis[1] <table><tr><td>Cell Line:</td><td>APC mutant COLO320DM colorectal tumour cells</td></tr><tr><td>Concentration:</td><td>1, 3, 10 μM</td></tr><tr><td>Incubation Time:</td><td>24 h</td></tr><tr><td>Result:</td><td>Increased AXIN2 protein levels and decreased 尾-catenin levels.</td></tr></table>				Cell Line:	APC mutant COLO320DM colorectal tumour cells	Concentration:	1, 3, 10 μM	Incubation Time:	24 h	Result:	Increased AXIN2 protein levels and decreased 尾-catenin levels.									
Cell Line:	APC mutant COLO320DM colorectal tumour cells																				
Concentration:	1, 3, 10 μM																				
Incubation Time:	24 h																				
Result:	Increased AXIN2 protein levels and decreased 尾-catenin levels.																				
In Vivo	MSC2504877 (30 mg/kg; 口服; 一次) 抑制小鼠体内的 TNKS 和 Wnt 信号传导[1]。 MSC2504877 (50 mg/kg+palbociclib 150mg/kg; 口服; 一次) 抑制体内 Apc 缺陷细胞的过度增殖[1]。 <table><tr><td>Animal Model:</td><td>CB17 SCID mice (APC mutant COLO320DM tumour cell xenografts)[1]</td></tr><tr><td>Dosage:</td><td>30 mg/kg</td></tr><tr><td>Administration:</td><td>P.o.; once</td></tr><tr><td>Result:</td><td>Elicited an increase in both TNKS and AXIN2 levels in tumours, peaking at 6–10 hours after drug administration and falling 18 hours after.</td></tr></table> <table><tr><td>Animal Model:</td><td>Villin-CreERT2; Apcfl/fl mice[1]</td></tr><tr><td>Dosage:</td><td>50 mg/kg + palbociclib (150 mg/kg)</td></tr><tr><td>Administration:</td><td>P.o.; once</td></tr><tr><td>Result:</td><td>Suppressed the expression of the archetypal Wnt target gene and stem cell marker Lgr5 and combination drug treatment caused a profound increase in nuclear p21.</td></tr></table>				Animal Model:	CB17 SCID mice (APC mutant COLO320DM tumour cell xenografts)[1]	Dosage:	30 mg/kg	Administration:	P.o.; once	Result:	Elicited an increase in both TNKS and AXIN2 levels in tumours, peaking at 6–10 hours after drug administration and falling 18 hours after.	Animal Model:	Villin-CreERT2; Apcfl/fl mice[1]	Dosage:	50 mg/kg + palbociclib (150 mg/kg)	Administration:	P.o.; once	Result:	Suppressed the expression of the archetypal Wnt target gene and stem cell marker Lgr5 and combination drug treatment caused a profound increase in nuclear p21.	
Animal Model:	CB17 SCID mice (APC mutant COLO320DM tumour cell xenografts)[1]																				
Dosage:	30 mg/kg																				
Administration:	P.o.; once																				
Result:	Elicited an increase in both TNKS and AXIN2 levels in tumours, peaking at 6–10 hours after drug administration and falling 18 hours after.																				
Animal Model:	Villin-CreERT2; Apcfl/fl mice[1]																				
Dosage:	50 mg/kg + palbociclib (150 mg/kg)																				
Administration:	P.o.; once																				
Result:	Suppressed the expression of the archetypal Wnt target gene and stem cell marker Lgr5 and combination drug treatment caused a profound increase in nuclear p21.																				
Solvent&Solubility	细胞实验: DMSO 中的溶解度 : 125 mg/mL (442.73 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响, 请使用新开封的 DMSO) <table><tr><td rowspan="4">Preparing Stock Solutions</td><td> Solvent / Mass Concentration </td><td>1 mg</td><td>5 mg</td><td>10 mg</td></tr><tr><td>1 mM</td><td>3.5418 mL</td><td>17.7091 mL</td><td>35.4183 mL</td></tr><tr><td>5 mM</td><td>0.7084 mL</td><td>3.5418 mL</td><td>7.0837 mL</td></tr><tr><td>10 mM</td><td>0.3542 mL</td><td>1.7709 mL</td><td>3.5418 mL</td></tr></table> * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液; 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。 储备液的保存方式和期限: -80°C, 6 months; -20°C, 1 month. -80°C 储存时, 请在 6 个月内使用, -20°C				Preparing Stock Solutions	Solvent / Mass Concentration	1 mg	5 mg	10 mg	1 mM	3.5418 mL	17.7091 mL	35.4183 mL	5 mM	0.7084 mL	3.5418 mL	7.0837 mL	10 mM	0.3542 mL	1.7709 mL	3.5418 mL
Preparing Stock Solutions	Solvent / Mass Concentration	1 mg	5 mg	10 mg																	
	1 mM	3.5418 mL	17.7091 mL	35.4183 mL																	
	5 mM	0.7084 mL	3.5418 mL	7.0837 mL																	
	10 mM	0.3542 mL	1.7709 mL	3.5418 mL																	



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyyw@sina.com

	储存时, 请在 1 个月内使用。
参考文献	[1]. Menon M, et al. A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors. Sci Rep. 2019 Jan 17;9(1):201.

完整储备液配制表:

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液; 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。储备液的保存方式和期限: -80°C, 6 months; -20°C, 1 month。-80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。

可选溶剂	质量 溶剂体积 浓度	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.5418 mL	17.7091 mL	35.4183 mL	88.5457 mL
	5 mM	0.7084 mL	3.5418 mL	7.0837 mL	17.7091 mL
	10 mM	0.3542 mL	1.7709 mL	3.5418 mL	8.8546 mL
	15 mM	0.2361 mL	1.1806 mL	2.3612 mL	5.9030 mL
	20 mM	0.1771 mL	0.8855 mL	1.7709 mL	4.4273 mL
	25 mM	0.1417 mL	0.7084 mL	1.4167 mL	3.5418 mL
	30 mM	0.1181 mL	0.5903 mL	1.1806 mL	2.9515 mL
	40 mM	0.0885 mL	0.4427 mL	0.8855 mL	2.2136 mL
	50 mM	0.0708 mL	0.3542 mL	0.7084 mL	1.7709 mL
	60 mM	0.0590 mL	0.2952 mL	0.5903 mL	1.4758 mL
	80 mM	0.0443 mL	0.2214 mL	0.4427 mL	1.1068 mL
	100 mM	0.0354 mL	0.1771 mL	0.3542 mL	0.8855 mL